Takeda Would See Added Costs Under U.S. FDA Plan
This article was originally published in PharmAsia News
A plan under review by the U.S. FDA could have an impact on Japan's Takeda Pharmaceutical and its diabetes drugs worth $2.9 billion in sales. The U.S. agency is considering raising standards that would require existing and new diabetes drugs to have a positive impact on cardiovascular disease and the life span of the patient. That could mean an end to the use of surrogate endpoints currently relied on by drug makers to measure benchmarks. If the FDA moves in that direction, Takeda, GlaxoSmithKline and other makers of diabetes drugs could be required to conduct additional studies to show the improvements. (Click here for more - a subscription may be required
You may also be interested in...
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.